Recent developments on immunotherapy for brain cancer

Expert Opinion on Emerging Drugs

Volumn 17, Issue 2, 2012, Pages 181-202

  Wainwright, Derek A ^a   Nigam, Pragati ^a   Thaci, Bart ^a   Dey, Mahua ^a   Lesniak, MacIej S ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

CTLA 4; Glioblastoma; Glioma; IDO; PD 1; Rindopepimut; TGF ; Treg

Indexed keywords

ANTICONVULSIVE AGENT; BEVACIZUMAB; CAPECITABINE; CELECOXIB; CINTREDEKIN BESUDOTOX; CRM 107; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACLIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EVEROLIMUS; IMATINIB; IMMUNOTOXIN; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; INTERLEUKIN 2; INTERLEUKIN 4; IPILIMUMAB; LOMUSTINE; LY 2109761; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NIVOLUMAB; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; PEGINTERFERON ALPHA2B; PEPTIDE; RAPAMYCIN; RESVERATROL; RINDOPEPIMUT; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; TIOGUANINE; TP 38; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; BLOOD BRAIN BARRIER; BLURRED VISION; BRAIN HERNIA; BURNING SENSATION; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHILL; COLITIS; COUGHING; CYTOKINE INDUCED KILLER CELL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DIARRHEA; DISEASE SEVERITY; DNA DAMAGE; DROWSINESS; DRUG WITHDRAWAL; EDEMA; FEVER; GENE EXPRESSION; GENE MUTATION; GLIOBLASTOMA; GLIOMA; HEADACHE; HEALTH CARE COST; HEPATITIS; HUMAN; HYPOPHYSITIS; IMMUNE SYSTEM; IMMUNOCOMPETENCE; INFECTION; INTRACRANIAL PRESSURE; LOW DRUG DOSE; LYMPHOCYTOPENIA; NAUSEA AND VOMITING; NEPHRITIS; NONHUMAN; ONCOGENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PDGFRA GENE; QUALITY OF LIFE; RASH; REGULATORY T LYMPHOCYTE; REVIEW; RHABDOMYOSARCOMA; SEIZURE; SORE THROAT; SOX GENE; STEM CELL TRANSPLANTATION; SWELLING; TUMOR CELL; TUMOR MODEL; UVEITIS;

ANIMALS; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84861589683     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2012.679929     Document Type: Review

References (183)

1. de Micco C. Immunology of tumors of the central nervous system. Bull Cancer 1989;76(1):17-31
2. Sawamura Y, de Tribolet N. Immunobiology of brain tumors. Adv Tech Stand Neurosurg 1990;17:3-64
3. Reardon DA, Wen PY. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist 2006;11(2):152-64 (Pubitemid 43261762)
4. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-96 (Pubitemid 40349501)
5. Bhondeley MK, Mehra RD, Mehra NK, et al. Imbalances in T cell subpopulations in human gliomas. J Neurosurg 1988;68(4):589-93
6. Black KL, Chen K, Becker DP, Merrill JE. Inflammatory leukocytes associated with increased immunosuppression by glioblastoma. J Neurosurg 1992;77(1):120-6
7. Huettner C, Czub S, Kerkau S, et al. Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vitro. Anticancer Res 1997;17(5A):3217-24 (Pubitemid 27522273)
8. Huettner C, Paulus W, Roggendorf W. Increased amounts of IL-10 mRNA in anaplastic astrocytomas and glioblastoma multiforme. Verh Dtsch Ges Pathol 1994;78:418-22
9. Huettner C, Paulus W, Roggendorf W. Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas. Am J Pathol 1995;146(2):317-22
10. Tran TT, Uhl M, Ma JY, et al. Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model. Neuro Oncol 2007;9(3):259-70 (Pubitemid 47169658)
11. Mitchell DA, Cui X, Schmittling RJ, et al. Monoclonal antibody blockade of IL-2 receptor alpha during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood 2011;118(11):3003-12
12. Curtin JF, Candolfi M, Fakhouri TM, et al. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. PLoS One 2008;3(4):e1983
13. Rolle CE, Sengupta S, Lesniak MS. Challenges in clinical design of immunotherapy trials for malignant glioma. Neurosurg Clin N Am 2010;21(1):201-14
14. Stavrou D, Anzil AP, Weidenbach W, Rodt H. Immunofluorescence study of lymphocytic infiltration in gliomas. Identification of T-lymphocytes. J Neurol Sci 1977;33(1-2):275-82 (Pubitemid 8143206)
15. Clark WC, Bressler J. Transforming growth factor-beta-like activity in tumors of the central nervous system. J Neurosurg 1988;68(6):920-4
16. Sawamura Y, Abe H, Aida T, et al. Isolation and in vitro growth of glioma-infiltrating lymphocytes, and an analysis of their surface phenotypes. J Neurosurg 1988;69(5):745-50
17. El Andaloussi A, Han Y, Lesniak MS. Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. J Neurosurg 2006;105(3):430-7 (Pubitemid 44358755)
18. El Andaloussi A, Lesniak MS. An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol 2006;8(3):234-43 (Pubitemid 46542648)
19. Fecci PE, Mitchell DA, Whitesides JF, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 2006;66(6):3294-302
20. Kong LY, Wei J, Sharma AK, et al. A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunol Immunother 2009;58(7):1023-32
21. Banissi C, Ghiringhelli F, Chen L, Carpentier AF. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol Immunother 2009;58(10):1627-34
22. Maes W, Rosas GG, Verbinnen B, et al. DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma. Neuro Oncol 2009;11(5):529-42
23. Sengupta S, Nandi S, Hindi ES, et al. Short hairpin RNA-mediated fibronectin knockdown delays tumor growth in a mouse glioma model. Neoplasia 2010;12(10):837-47
24. Morimura T, Neuchrist C, Kitz K, et al. Monocyte subpopulations in human gliomas: expression of Fc and complement receptors and correlation with tumor proliferation. Acta Neuropathol 1990;80(3):287-94 (Pubitemid 20220544)
25. Kiefer R, Supler ML, Toyka KV, Streit WJ. In situ detection of transforming growth factor-beta mRNA in experimental rat glioma and reactive glial cells. Neurosci Lett 1994;166(2):161-4 (Pubitemid 24053818)
26. Rossler K, Neuchrist C, Kitz K, et al. Expression of leucocyte adhesion molecules at the human blood-brain barrier (BBB). J Neurosci Res 1992;31(2):365-74
27. Stewart PA, Magliocco M, Hayakawa K, et al. A quantitative analysis of blood-brain barrier ultrastructure in the aging human. Microvasc Res 1987;33(2):270-82 (Pubitemid 17065264)
28. Lowe D, Schieweck C, Meier-Ruge W, et al. The effect of "ouabain" on the ultrastructure of cerebral arterioles and surrounding tissue, studied by a cannulation of a cerebral artery. Res Exp Med (Berl) 1975;166(2):97-114
29. Allt G, Lawrenson JG. Pericytes: cell biology and pathology. Cells Tissues Organs 2001;169(1):1-11 (Pubitemid 32437039)
30. Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res 2005;97(6):512-23 (Pubitemid 41361741)
31. Janzer RC, Raff MC. Astrocytes induce blood-brain barrier properties in endothelial cells. Nature 1987;325(6101):253-7 (Pubitemid 17049884)
32. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10(9):942-9 (Pubitemid 39273735)
33. Jordan JT, Sun W, Hussain SF, et al. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother 2008;57(1):123-31 (Pubitemid 350043644)
34. Huang H, Liu Y, Xiang J. Synergistic effect of adoptive T-cell therapy and intratumoral interferon gamma-inducible protein-10 transgene expression in treatment of established tumors. Cell Immunol 2002;217(1-2):12-22 (Pubitemid 35352156)
35. Riva M, Salmaggi A, Marchioni E, et al. Tumour-associated epilepsy: clinical impact and the role of referring centres in a cohort of glioblastoma patients. A multicentre study from the Lombardia Neurooncology Group. Neurol Sci 2006;27(5):345-51 (Pubitemid 44824540)
36. Van Meir EG, Hadjipanayis CG, Norden AD, et al. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010;60(3):166-93
37. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352(10):997-1003 (Pubitemid 40349502)
38. Gorlia T, van den Bent MJ, Hegi ME, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 2008;9(1):29-38
39. McLendon R, Friedman A, Bisner D, et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455(7216):1061-8
40. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17(1):98-110
41. Murat A, Migliavacca E, Gorlia T, et al. Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 2008;26(18):3015-24
42. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444(7120):756-60 (Pubitemid 44949604)
43. Bleau AM, Hambardzumyan D, Ozawa T, et al. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009;4(3):226-35
44. Wei J, Barr J, Kong LY, et al. Glioma-associated cancer-initiating cells induce immunosuppression. Clin Cancer Res 2010;16(2):461-73
45. Pistollato F, Abbadi S, Rampazzo E, et al. Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma. Stem Cells 2010;28(5):851-62
46. Spence AM, Muzi M, Swanson KR, et al. Regional hypoxia in glioblastoma multiforme quantified with [18F] fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res 2008;14(9):2623-30
47. Wynn ML, Merajver SD, Schnell S. Unraveling the complex regulatory relationships between metabolism and signal transduction in cancer. Adv Exp Med Biol 2012;736:179-89
48. Khan RB, Raizer JJ, Malkin MG, et al. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro Oncol 2002;4(1):39-43 (Pubitemid 34269465)
49. Fadul CE, Fisher JL, Gui J, et al. Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. Neuro Oncol 2011;13(4):393-400
50. Jain RK, di Tomaso E, Duda DG, et al. Angiogenesis in brain tumours. Nat Rev Neurosci 2007;8(8):610-22 (Pubitemid 47093931)
51. Salmaggi A, Eoli M, Frigerio S, et al. Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neurooncol 2003;62(3):297-303 (Pubitemid 36591966)
52. Schmidt NO, Westphal M, Hagel C, et al. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer 1999;84(1):10-18 (Pubitemid 29059101)
53. Zhou YH, Tan F, Hess KR, Yung WK. The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res 2003;9(9):3369-75 (Pubitemid 37082732)
54. Vredenburgh JJ, Desjardins A, Herndon JE II, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13(4):1253-9 (Pubitemid 46424067)
55. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27(28):4733-40
56. Kreisl TN, Zhang W, Odia Y, et al. A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro Oncol 2011;13(10):1143-50
57. De Braganca KC, Janjigian YY, Azzoli CG, et al. Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. J Neurooncol 2010;100(3):443-7
58. Chira C, Jacob J, Derhem N, et al. Preliminary experience of whole-brain radiation therapy (WBRT) in breast cancer patients with brain metastases previously treated with bevacizumab-based chemotherapy. J Neurooncol 2011;105(2):401-8
59. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005;69(Suppl 3):11-16 (Pubitemid 41680948)
60. Castro MG, Candolfi M, Kroeger K, et al. Gene therapy and targeted toxins for glioma. Curr Gene Ther 2011;11(3):155-80
61. Reardon DA, Wen PY, Desjardins A, et al. Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther 2008;8(4):541-53 (Pubitemid 351570416)
62. American Cancer Society. Cancer facts and figures 2011. 2011; Available from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/ documents/document/acspc-031941.pdf
63. Kutikova L, Bowman L, Chang S, Long S. How costly is brain cancer? Healthcare services use and costs from across the US. J Clin Oncol 2004;22(14S):1559
64. Patterson H. The financial impact of brain tumors on patients and families: a summary of findings. National Brain Tumor Foundation 2007; Available from: http://www.braintumor.org/assets/docs/Nobody-Can-Afford-a-Brain-Tumor.pdf
65. Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011;103(2):117-28
66. Ahmed AU, Rolle CE, Tyler MA, et al. Bone marrow mesenchymal stem cells loaded with an oncolytic adenovirus suppress the anti-adenoviral immune response in the cotton rat model. Mol Ther 2010;18(10):1846-56
67. Wainwright DA, Sengupta S, Han Y, Lesniak MS. Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors. Neuro Oncol 2011;13(12):1308-23
68. Tran Thang NN, Derouazi M, Philippin G, et al. Immune infiltration of spontaneous mouse astrocytomas is dominated by immunosuppressive cells from early stages of tumor development. Cancer Res 2010;70(12):4829-39
69. Heimberger AB, Kong LY, Abou-Ghazal M, et al. The role of tregs in human glioma patients and their inhibition with a novel STAT-3 inhibitor. Clin Neurosurg 2009;56:98-106
70. Heimberger AB, Abou-Ghazal M, Reina-Ortiz C, et al. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res 2008;14(16):5166-72
71. Jacobs JF, Idema AJ, Bol KF, et al. Prognostic significance and mechanism of Treg infiltration in human brain tumors. J Neuroimmunol 2010;225(1-2):195-9
72. Bruna A, Darken RS, Rojo F, et al. High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 2007;11(2):147-60 (Pubitemid 46209848)
73. Jung Y, Joo KM, Seong DH, et al. Identification of prognostic biomarkers for glioblastomas using protein. Int J Oncol 2012;40(4):1122-32
74. Seoane J, Le HV, Shen L, et al. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 2004;117(2):211-23 (Pubitemid 38496241)
75. Nitta T, Hishii M, Sato K, Okumura K. Selective expression of interleukin-10 gene within glioblastoma multiforme. Brain Res 1994;649(1-2):122-8 (Pubitemid 24197203)
76. Wang C, Cao S, Yan Y, et al. TLR9 expression in glioma tissues correlated to glioma progression and the prognosis of GBM patients. BMC Cancer 2010;10:415
77. Urry Z, et al. Ligation of TLR9 induced on human IL-10-secreting Tregs by 1alpha,25-dihydroxyvitamin D3 abrogates regulatory function. J Clin Invest 2009;119(2):387-98
78. Jacobs C, Duewell P, Heckelsmiller K, et al. An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma. Int J Cancer 2011;128(4):897-907
79. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008;359(5):492-507
80. Heimberger AB, Hlatky R, Suki D, et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 2005;11(4):1462-6 (Pubitemid 40315227)
81. Del Vecchio CA, Wong AJ. Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme. Curr Opin Mol Ther 2010;12(6):741-54
82. Debinski W, Obiri NI, Powers SK, et al. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin Cancer Res 1995;1(11):1253-8
83. Debinski W, Gibo DM, Slagle B, et al. Receptor for interleukin 13 is abundantly and specifically over-expressed in patients with glioblastoma multiforme. Int J Oncol 1999;15(3):481-6
84. Joshi BH, Leland P, Asher A, et al. In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures. Cancer Res 2001;61(22):8058-61 (Pubitemid 33091589)
85. Mohanam S, et al. Proteolysis and invasiveness of brain tumors: role of urokinase-type plasminogen activator receptor. J Neurooncol 1994;22(2):153-60
86. Yamamoto M, Sawaya R, Mohanam S, et al. Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo. Cancer Res 1994;54(14):3656-61 (Pubitemid 24241173)
87. Li YM, Hall WA. Targeted toxins in brain tumor therapy. Toxins (Basel) 2010;2(11):2645-62
88. Kunwar S, et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 2007;25(7):837-44 (Pubitemid 350002884)
89. Rand RW, Kreitman RJ, Patronas N, et al. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 2000;6(6):2157-65 (Pubitemid 30399180)
90. Puri RK. Development of a recombinant interleukin-4-Pseudomonas exotoxin for therapy of glioblastoma. Toxicol Pathol 1999;27(1):53-7 (Pubitemid 29075745)
91. Kunwar S, Chang S, Westphal M. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol 2010;12(8):871-81
92. Mueller S, Polley MY, Lee B, et al. Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study. J Neurooncol 2011;101(2):267-77
93. Sampson JH, Akabani G, Archer GE, et al. Progress report of a phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 2003;65(1):27-35 (Pubitemid 37441312)
94. Rustamzadeh E, Li C, Doumbia S, et al. Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme. J Neurooncol 2003;65(1):63-75 (Pubitemid 37441314)
95. Rustamzadeh E, Hall WA, Todhunter DA, et al. Intracranial therapy of glioblastoma with the fusion protein DTAT in immunodeficient mice. Int J Cancer 2007;120(2):411-19 (Pubitemid 44956855)
96. Vallera DA, Li C, Jin N, et al. Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT. J Natl Cancer Inst 2002;94(8):597-606 (Pubitemid 34498647)
97. Todhunter DA, Hall WA, Rustamzadeh E, et al. A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model. Protein Eng Des Sel 2004;17(2):157-64 (Pubitemid 38477742)
98. Rustamzadeh E, et al. Immunotoxin pharmacokinetics: a comparison of the anti-glioblastoma bi-specific fusion protein (DTAT13) to DTAT and DTIL13. J Neurooncol 2006;77(3):257-66 (Pubitemid 44404391)
99. Rustamzadeh E, et al. Intracranial therapy of glioblastoma with the fusion protein DTIL13 in immunodeficient mice. Int J Cancer 2006;118(10):2594- 601
100. Heimberger AB, Sampson JH. The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert Opin Biol Ther 2009;9(8):1087-98
101. Heimberger AB, Sun W, Hussain SF, et al. Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro Oncol 2008;10(1):98-103 (Pubitemid 351250906)
102. Wheeler CJ, Das A, Liu G, et al. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 2004;10(16):5316-26 (Pubitemid 39100466)
103. Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 2005;11(15):5515-25 (Pubitemid 41060828)
104. Sampson JH, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010;28(31):4722-9
105. Sampson JH, Archer GE, Mitchell DA, et al. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther 2009;8(10):2773-9
106. Schuler G, Schuler-Thurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003;15(2):138-47 (Pubitemid 36287518)
107. Curtin JF, King GD, Barcia C, et al. Fms-like tyrosine kinase 3 ligand recruits plasmacytoid dendritic cells to the brain. J Immunol 2006;176(6):3566-77 (Pubitemid 43364004)
108. Ali S, Curtin JF, Zirger JM, et al. Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. Mol Ther 2004;10(6):1071-84 (Pubitemid 39625251)
109. Mineharu Y, King GD, Muhammad AK, et al. Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design. Clin Cancer Res 2011;17(14):4705-18
110. Fecci PE, Ochiai H, Mitchell DA, et al. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res 2007;13(7):2158-67 (Pubitemid 46649886)
111. Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 Blockade with Ipilimumab: Long-Term Follow-up of 177 Patients with Metastatic Melanoma. Clin Cancer Res 2012
112. Li L, et al. A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme. J Neurosurg 2010;113(2):192-8
113. Veeravagu A, Liu Z, Niu G, et al. Integrin alphavbeta3-targeted radioimmunotherapy of glioblastoma multiforme. Clin Cancer Res 2008;14(22):7330-9
114. Aghi M, Martuza RL. Oncolytic viral therapies-the clinical experience. Oncogene 2005;24(52):7802-16 (Pubitemid 41670681)
115. Niranjan A, Moriuchi S, Lunsford LD, et al. Effective treatment of experimental glioblastoma by HSV vector-mediated TNF alpha and HSV-tk gene transfer in combination with radiosurgery and ganciclovir administration. Mol Ther 2000;2(2):114-20
116. King GD, Kroeger KM, Bresee CJ, et al. Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits. Mol Ther 2008;16(4):682-90 (Pubitemid 351426169)
117. King GD, Muhammad AK, Curtin JF, et al. Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model. Neuro Oncol 2008;10(1):19-31 (Pubitemid 351250897)
118. Ghulam Muhammad AK, Candolfi M, et al. Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression. Clin Cancer Res 2009;15(19):6113-27
119. Okada H, Pollack IF, Lotze MT, et al. Gene therapy of malignant gliomas: a phase I study of IL-4-HSV-TK gene-modified autologous tumor to elicit an immune response. Hum Gene Ther 2000;11(4):637-53 (Pubitemid 30134307)
120. Ilvesaro JM, Merrell MA, Li L, et al. Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion. Mol Cancer Res 2008;6(10):1534-43
121. Schmausser B, Andrulis M, Endrich S, et al. Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. Int J Med Microbiol 2005;295(3):179-85 (Pubitemid 40776102)
122. Droemann D, et al. Human lung cancer cells express functionally active Toll-like receptor 9. Respir Res 2005;6:1
123. Ilvesaro JM, Merrell MA, Swain TM, et al. Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate 2007;67(7):774-81 (Pubitemid 46709446)
124. Leng L, Jiang T, Zhang Y. TLR9 expression is associated with prognosis in patients with glioblastoma multiforme. J Clin Neurosci 2012;19(1):75-80
125. Merrell MA, Ilvesaro JM, Lehtonen N, et al. Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res 2006;4(7):437-47 (Pubitemid 44197039)
126. Grauer OM, Molling JW, Bennink E, et al. TLR ligands in the local treatment of established intracerebral murine gliomas. J Immunol 2008;181(10):6720-9
127. El Andaloussi A, Sonabend AM, Han Y, Lesniak MS. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. Glia 2006;54(6):526-35 (Pubitemid 44449333)
128. Meng Y, et al. Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int J Cancer 2005;116(6):992-7 (Pubitemid 41209208)
129. Zhang M, Kleber S, Rohrich M, et al. Blockade of TGF-beta signaling by the TGFbetaR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res 2011;71(23):7155-67
130. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012
131. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28(19):3167-75
132. Fourcade J, et al. CD8+ T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res 2012
133. Woo SR, Turnis ME, Goldberg MV, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012
134. Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009;206(13):3015-29
135. Amarnath S, Mangus CW, Wang JC, et al. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci Transl Med 2011;3(111):111ra120
136. Miyazaki T, Moritake K, Yamada K, et al. Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy. Laboratory investigation. J Neurosurg 2009;111(2):230-7
137. Avril T, Saikali S, Vauleon E, et al. Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions. J Neuroimmunol 2010;225(1-2):22-33
138. Chung DJ, et al. Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood 2009;114(3):555-63
139. Sharma MD, Baban B, Chandler P, et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 2007;117(9):2570-82 (Pubitemid 47494358)
140. Pallotta MT, Orabona C, Volpi C, et al. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol 2011;12(9):870-8
141. Mellor AL, Keskin DB, Johnson T, et al. Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J Immunol 2002;168(8):3771-6 (Pubitemid 34298376)
142. Huang L, Baban B, Johnson BA III, Mellor AL. Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege. Int Rev Immunol 2010;29(2):133-55
143. Heimberger AB, Sampson JH. Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? Neuro Oncol 2011;13(1):3-13
144. Wainwright DA, Sengupta S, Han Y, et al. The presence of IL-17A and T helper 17 cells in experimental mouse brain tumors and human glioma. PLoS One 2010;5(10):e15390
145. Nishikawa R, Ji XD, Harmon RC, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 1994;91(16):7727-31 (Pubitemid 24238258)
146. Nagane M, Coufal F, Lin H, et al. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 1996;56(21):5079-86 (Pubitemid 26374452)
147. Shinojima N, Tada K, Shiraishi S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003;63(20):6962-70 (Pubitemid 37322983)
148. Rahaman SO, Sharma P, Harbor PC, et al. IL-13R(alpha)2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells. Cancer Res 2002;62(4):1103-9 (Pubitemid 34160294)
149. Wu AH, Low WC. Molecular cloning and identification of the human interleukin 13 alpha 2 receptor (IL-13Ra2) promoter. Neuro Oncol 2003;5(3):179-87 (Pubitemid 36790347)
150. Joshi BH, Leland P, Silber J, et al. IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-Pseudomonas exotoxin fusion protein. Br J Cancer 2002;86(2):285-91 (Pubitemid 34185160)
151. Puri RK. Cytotoxins directed at interleukin-4 receptors as therapy for human brain tumors. Methods Mol Biol 2001;166:155-76
152. Heimberger AB, Archer GE, Crotty LE, et al. Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery 2002;50(1):158-64; discussion 164-6 (Pubitemid 41672565)
153. Heimberger AB, Crotty LE, Archer GE, et al. Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J Neuroimmunol 2000;103(1):16-25 (Pubitemid 30058249)
154. Cho DY, Yang WK, Lee HC, et al. Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial. World Neurosurg 2011
155. Chang CN, Huang YC, Yang DM, et al. A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma. J Clin Neurosci 2011;18(8):1048-54
156. Fadul CE, Fisher JL, Hampton TH, et al. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunother 2011;34(4):382-9
157. Okada H, Kalinski P, Ueda R, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 2011;29(3):330-6
158. Miyatake S, Handa H, Yamashita J, et al. Induction of human glioma-specific cytotoxic T-lymphocyte lines by autologous tumor stimulation and interleukin 2. J Neurooncol 1986;4(1):55-64 (Pubitemid 16007562)
159. Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA. Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. Preliminary report. J Neurosurg 1986;64(5):743-9 (Pubitemid 16115351)
160. Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA. Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial. Cancer Res 1986;46(4 Pt 2):2101-4 (Pubitemid 16117915)
161. Jacobs SK, Wilson DJ, Melin G, et al. Interleukin-2 and lymphokine activated killer (LAK) cells in the treatment of malignant glioma: clinical and experimental studies. Neurol Res 1986;8(2):81-7 (Pubitemid 16098556)
162. Kitahara T, Watanabe O, Yamaura A, et al. Establishment of interleukin 2 dependent cytotoxic T lymphocyte cell line specific for autologous brain tumor and its intracranial administration for therapy of the tumor. J Neurooncol 1987;4(4):329-36 (Pubitemid 17037579)
163. Yoshida S, Tanaka R, Takai N, Ono K. Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors. Cancer Res 1988;48(17):5011-16
164. Hau P, Jachimczak P, Bogdahn U. Treatment of malignant gliomas with TGF-beta2 antisense oligonucleotides. Expert Rev Anticancer Ther 2009;9(11):1663-74
165. Hau P, Jachimczak P, Schlaier J, Bogdahn U. TGF-beta2 signaling in high-grade gliomas. Curr Pharm Biotechnol 2011
166. Hau P, Jachimczak P, Schlingensiepen R, et al. Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides 2007;17(2):201-12 (Pubitemid 47124417)
167. Schlingensiepen KH, Fischer-Blass B, Schmaus S, Ludwig S. Antisense therapeutics for tumor treatment: the TGF-beta2 inhibitor AP 12009 in clinical development against malignant tumors. Recent Results Cancer Res 2008;177:137-50
168. Zhang M, Kleber S, Rohrich M, et al. Blockade of TGF-beta signaling by the TGFbetaR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res 2011;71(23):7155-67
169. Zhang M, Herion TW, Timke C, et al. Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-beta receptor I kinase inhibitor LY2109761. Neoplasia 2011;13(6):537-49
170. Lohr J, Ratliff T, Huppertz A, et al. Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-beta. Clin Cancer Res 2011;17(13):4296-308
171. Olson JJ, McKenzie E, Skurski-Martin M, et al. Phase I analysis of BCNU-impregnated biodegradable polymer wafers followed by systemic interferon alfa-2b in adults with recurrent glioblastoma multiforme. J Neurooncol 2008;90(3):293-9
172. Buckner JC, Brown LD, Kugler JW, et al. Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma. J Neurosurg 1995;82(3):430-5
173. Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme. Br J Cancer 2009;101(4):615-20
174. Dillman RO, Shea WM, Tai DF, et al. Interferon-alpha2a and 13-cis-retinoic acid with radiation treatment for high-grade glioma. Neuro Oncol 2001;3(1):35-41 (Pubitemid 33685584)
175. Grauer OM, Nierkens S, Bennink E, et al. CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer 2007;121(1):95-105 (Pubitemid 46753856)
176. Grauer OM, Sutmuller RP, van Maren W, et al. Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model. Int J Cancer 2008;122(8):1794-802 (Pubitemid 351413426)
177. Hussain SF, Kong LY, Jordan J, et al. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 2007;67(20):9630-6 (Pubitemid 47621208)
178. Brantley EC, Benveniste EN. Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas. Mol Cancer Res 2008;6(5):675-84
179. Nogueira L, Ruiz-Ontanon P, Vazquez-Barquero A, et al. The NFkappaB pathway: a therapeutic target in glioblastoma. Oncotarget 2011;2(8):646-53
180. Curti A, Pandolfi S, Valzasina B, et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25-into CD25+ T regulatory cells. Blood 2007;109(7):2871-7 (Pubitemid 46482083)
181. Cohen AD, Schaer DA, Liu C, et al. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS One 2010;5(5):e10436
182. Raychaudhuri B, Rayman P, Ireland J, et al. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol 2011;13(6):591-9
183. Wing K, Yamaguchi T, Sakaguchi S. Cell-autonomous and-non-autonomous roles of CTLA-4 in immune regulation. Trends Immunol 2011;32(9):428-33